Laboratory Corporation of America has launched its Epi proColon test for colorectal cancer, under a joint marketing agreement with Polymedco.
Epi proColon was developed by Epigenomics AG and is the first DNA-based test with this indication, according to the company.
The test, approved last month, pinpoints Epigenomics proprietary Septin9 DNA biomarker in cell-free DNA. The new addition expands the company’s existing portfolio of colorectal cancer offerings. — Anisa Jibrell